Simplex Trading’s Quince Therapeutics QNCX Stock Holding History

Simplex Trading’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$404	Buy	20 +17	+567%	+$3.41K	﹤0.01%	8760
2025 Q4	$1.68K	Buy	+3	New	+$1.51K	﹤0.01%	7888
2023 Q1	–	Sell	-415	Closed	-$52K	–	9918
2022 Q4	$52K	Buy	415 +1	+0.2%	+$167	﹤0.01%	5840
2022 Q3	$110K	Sell	414 -52	-11%	-$19.8K	﹤0.01%	5386
2022 Q2	$206K	Sell	466 -246	-35%	-$174K	﹤0.01%	4563
2022 Q1	$880K	Buy	712 +514	+260%	+$699K	﹤0.01%	3067
2021 Q4	$498K	Buy	198 +171	+633%	+$1.04M	﹤0.01%	3815
2021 Q3	$297K	Hold	27	–	–	﹤0.01%	4922
2021 Q2	$286K	Buy	+27	New	+$226K	﹤0.01%	5059
2021 Q1	–	Hold	0	–	–	–	8092
2020 Q4	–	Hold	0	–	–	–	6319

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading's QNCX Position: Q1 2026 in Review

Simplex Trading reduced its Quince Therapeutics (QNCX) stake by 7.9% in Q1 2026, selling an estimated $13.2K and leaving 770 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6966.

Simplex Trading first reported a position in QNCX in Q3 2020 and has held it in 10 quarters since. The position peaked at $560K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Simplex Trading held 770 shares of Quince Therapeutics worth $15.6K as of Q1 2026.
Simplex Trading sold 66 Quince Therapeutics shares in Q1 2026, an estimated $13.2K.
Quince Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6966 holding.
Simplex Trading first reported a position in Quince Therapeutics in Q3 2020 and has held it in 10 quarters since.
Simplex Trading's Quince Therapeutics position peaked at $560K in Q4 2025.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.